US-based biotech company Inspyr Therapeutics has initiated its Phase II clinical trial by dosing the first patient with mipsagargin to treat newly diagnosed prostate cancer.

Mipsagargin is developed as a pro-drug that modifies itself into an active form only after it reaches the inside of the tumour.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is designed to target prostate-specific membrane antigen (PSMA), an enzyme expressed on the surface of prostate-cancer cells and on tumour-associated blood vessels in other tumour types.

The Phase II trial is designed as an open-label, single-arm study and will be conducted at the University of Texas Health Science Centre (UTHealth), Houston.

"Mipsagargin presents a novel tumour-targeting approach to treating patients newly diagnosed with prostate cancer."

The trial will involve patients with treatment-naïve prostate cancer before surgical removal of the tumour.

See Also:

During the trial, the patients will be administered with mipsagargin, injected intravenously for the first three consecutive days of a 28-day cycle.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial is aimed at determining the efficacy of mipsagargin on the perfusion and volume of the prostate.

University of Texas / Memorial Hermann Cancer Centre professor and director and principal trial investigator Robert Amato said: “Mipsagargin presents a novel tumour-targeting approach to treating patients newly diagnosed with prostate cancer.

“My colleagues at UTHealth are focused on improving treatment options for prostate cancer patients, and we look forward to evaluating mipsagargin’s effectiveness in disrupting the blood supply of prostate tumours and killing prostate cancer cells, which could lead to tumour regression and potentially improved survival rates for patients diagnosed with this type of cancer.”

The company is expecting the top-line results of the clinical trial next year.